Filing Details

Accession Number:
0001209191-21-002374
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-06 19:30:41
Reporting Period:
2021-01-04
Accepted Time:
2021-01-06 19:30:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1426332 Ngm Biopharmaceuticals Inc NGM Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1642996 Jin-Long Chen 333 Oyster Point Boulevard
South San Francisco CA 94080
Chief Scientific Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-01-04 24,630 $29.27 870,375 No 4 S Direct
Common Stock Disposition 2021-01-04 370 $30.26 870,005 No 4 S Direct
Common Stock Acquisiton 2021-01-05 150,000 $0.60 1,020,005 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-01-05 150,000 $0.00 150,000 $0.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-02-10 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $28.945 to $29.56. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Pursuant to its terms, the option to purchase these shares expires on February 10, 2021, unless earlier exercised. This transaction represents the exercise of the shares under this incentive stock option by the reporting person prior to the expiration date.
  4. Fully vested.